One of the most important advances in malaria treatment has occurred as the WHO has recently given its approval on a unique medicine for babies who have this health problem.
Coartem Baby (artemether-lumefantrine) by Novartis has just got the green light from Swissmedic and is to become the world’s first-ever clinically tested treatment for babies suffering from malaria.
Ahead of #WorldMalariaDay (25 April), WHO has prequalified the first malaria treatment designed specifically for newborns and young infants (weighing 2–5 kg). This is a major step towards closing a critical treatment gap for the most vulnerable. Read more: https://t.co/DTKzL6rwh3… pic.twitter.com/EIeB2xLSsG
— World Health Organization (WHO) (@WHO) April 24, 2026
Overview of Coartem Baby
Coartem Baby, or Riamet Baby in some regions, is specially formulated to treat infants under the weight of 5 kg.
Previously, the following factors made many medical practitioners concerned when dealing with infants affected with malaria:
- Impropriate dosing
- Increased risks of toxicity
- Lack of safety studies
The unique formula is easy to administer, dissolvable in breast milk, and has special flavorings.
Filling Critical Treatment Gaps in Africa
Malaria is one of the most fatal diseases in the world, coartem baby malaria treatment, with a disproportionately high prevalence in Africa.
Based on World Health Organization statistics:
- 263 million cases of malaria were recorded in 2023
- 597,000 people lost their lives due to malaria in 2023, especially in Africa
- Children below five accounted for 75 percent of deaths
Every year, about 30 million babies are born in Africa, where malaria transmission poses a risk, but babies under six months have not been part of any clinical trial.
Experts attribute this to a critical treatment gap that can be bridged by Coartem Baby.
Development of the Drug
Coartem Baby was developed in collaboration with MMV and supported by international scientific studies.
This approval is based on clinical results from the CALINA Phase II/III clinical trials, where the dose was adjusted to take into account the way infants’ bodies absorb drugs.
Eight countries in Africa have participated in the drug’s regulatory approval process and are anticipated to grant rapid access under the global health authorization by Swissmedic.
How the New Malaria Drug Operates
Coartem Baby is intended to address:
- Simple malaria infections
- Induced by either Plasmodium falciparum or a mixture of infections
This new preparation is formulated for use in babies who have a weight ranging from 2 kg to 5 kg.
Novartis to Bring Medication to the Market at Affordable Prices
Novartis claims that the new medication will be launched in the market in a predominantly nonprofit setting, which is geared towards reaching more malaria-affected populations.
The company has had an extensive track record when it comes to antimalarial medications, in the sense that:
- It has supplied over 1.1 billion antimalarial medications since 1999
- Over hundreds of millions of pediatric doses
An Important Breakthrough in the Battle Against Malaria
According to medical professionals, this is a very important breakthrough in decreasing infant mortality rates related to malaria cases.
Without any vaccines yet approved for use in babies, Coartem Baby might be helpful in:
- Reducing infant mortality rates
- Increasing early-stage treatment of malaria
- Improving public health efforts in Africa
Conclusion
The new Coartem Baby medicine can be considered an important achievement in the field of global health since it is the first treatment of malaria for babies that is both effective and safe.
As African countries start implementing it quickly, Coartem Baby might bridge the deadly gap in malaria treatment.
